Author

Mark M. Painter

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

SARS-CoV-2-specific monoclonal antibody AER002 in Long COVID: an exploratory randomized phase 2a mechanistic trial

Persistence of SARS-CoV-2 has been proposed as a biological driver of Long COVID, a disabling chronic illness with no proven treatments. We conducted an exploratory, placebo-controlled, double-blind, 2:1 randomized mechanistic trial (NCT05877508) of the SARS-CoV-2-specific monoclonal antibody AER002 in 36 participa...

M. Peluso, Dylan Ryder, T. Dalhuisen et al. · Nature Communications · 0 citations

Open access Aug 2026

Potent type-specific de novo antibodies complement broadly reactive imprinted antibodies in immune responses to SARS-CoV-2 variants

Hundreds of recall and de novo neutralizing monoclonal antibodies are isolated and characterized after sequential exposures to SARS-CoV-2 variants in ancestral-imprinted humans to reveal the distinct contributions of recall and de novo antibodies to a balanced immune response and underscore the benefit of updated boost...

T. Johnston, Shuk-Hang Li, M. Painter et al. · Nature Immunology · 2 citations

Open access Aug 2026

Vaccine imprinting drives increased SARS-CoV-2 variant infection in children

The dependence of effective variant-specific antibodies on vaccination history is shown which may explain birth-year influence on differential susceptibility to SARS-CoV-2 variants XFG and BA.3.3.2, and it is suggested that vaccination regimens in children should prioritize neutralization breadth.

T. Johnston, Rahul Subramanian, Wakinyan Benhamou et al. · bioRxiv · 0 citations